Here, we describe a new therapeutic strategy based on a single chain bispecific antibody (scDb-hERG1-β1) which targets a cancer-specific antigen, i.e., the complex formed by the K+ channel hERG1 and the β1 integrin (hERG1/β1 integrin complex). The gene discussed is KCNH2; the disease is cancer.